New drug tested for Tough-to-Treat blood cancers
NCT ID NCT05627856
Summary
This early-stage study is testing an experimental drug called GNC-038 in adults with certain aggressive types of lymphoma that have returned or not responded to prior treatments. The main goals are to find a safe dose, check for side effects, and see if the drug can shrink tumors. It is for patients who have already tried other standard therapies without success.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Guangdong Provincial People's Hospital
Guangzhou, Guangdong, 510120, China
-
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, 510050, China
Conditions
Explore the condition pages connected to this study.